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Abstract We employed cDNA representational difference
analysis to identify new genes that are upregulated by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in a human hepatoblasto-
ma cell line HepG2. We isolated several TCDD-responsive
cDNAs. Sequence analysis revealed that one of them encodes
E16/CD98LC/hLAT1, an integral membrane protein involved in
multiple cellular functions including cellular transport of L-type
amino acids. Northern blot analysis confirmed the TCDD-
dependent upregulation of the mRNA. Induction of E16/
CD98LC/hLAT1 mRNA by TCDD did not require de novo
protein synthesis as revealed by the experiment using cyclohex-
imide. Consistent with the changes at mRNA level, the transport
of 3H-leucine into HepG2 cells was significantly increased by
TCDD treatment. These findings provide a novel aspect of
biological effects of TCDD on human hepatocytes.
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1. Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related
halogenated aromatic hydrocarbons are potential environ-
mental contaminants that have a pleiotropic adverse biolog-
ical e¡ect on living animals. Exposure to TCDD leads to
tumor promotion, teratogenesis, immunosuppression, hepato-
toxicity, epithelial dysplasia, reproductive toxicity and thymic
atrophy [1,2]. Most of the e¡ects of TCDD are believed to be
mediated by aryl hydrocarbon receptor (AhR) that is a li-
gand-activated transcription factor belonging to basic helix-
loop-helix (bHLH)/PAS protein family [3]. In unstimulated
cells, AhR is present in the cytoplasm in association with
Hsp90. Upon TCDD binding, liganded AhR translocates
into nucleus and heterodimerizes with another bHLH/PAS
protein, aryl hydrocarbon nuclear translocator (ARNT). Sub-
sequently, AhR/ARNT complex binds to the speci¢c DNA
sequence (xenobiotic response element (XRE)) in the enhancer
region of target genes, and regulates their transcription. Thus,
initial AhR-mediated gene regulation does not require de
novo protein synthesis.
Most of the TCDD-responsive genes identi¢ed to date code
for enzymes associated with various metabolic pathways with-
in the liver, for instance, cytochrome P450 CYP1A1,
CYP1B1, aldehyde dehydrogenase, NADPH-quinone-oxido-
reductase, glutathione-S-transferase (GST) Ya, UDP-glucuro-
nosyltransferase 1A1 and ecto-ATPase [4^8]. However, con-
sidering the divergent biological e¡ects of TCDD like
teratogenesis and tumor promotion, genes associated with
cell division, cell cycle regulation or cell adhesion are likely
to be regulated by TCDD. We, therefore, endeavored to dis-
cover other TCDD-responsive genes.
We employed cDNA representational di¡erence analysis
(cDNA RDA) to isolate TCDD-responsive genes in human
hepatoblastoma cell line HepG2. cDNA RDA is a polymerase
chain reaction (PCR)-coupled subtractive enrichment proce-
dure for the isolation of di¡erentially expressed cDNAs
among two di¡erent cDNA populations (called Tester and
Driver) [9,10]. Usually, Driver cDNA population is subtracted
from Tester cDNA population by hybridization. Thus,
cDNAs present only in the Tester are enriched and ampli¢ed
by PCR. In order to identify genes that are directly upregu-
lated by TCDD, the Tester cDNA was prepared from the cells
that were pretreated with protein synthesis inhibitor cyclohex-
imide (CHX), followed by TCDD, and the Driver cDNA was
prepared from the cells treated with CHX alone. We cloned
several TCDD-responsive cDNAs. Sequence analysis revealed
that one of them encodes E16/CD98LC/hLAT1 [11^13].
2. Materials and methods
2.1. Cell culture
Human hepatoblastoma cell line HepG2 (ATCC HB-8065) was
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM; Nissui,
Tokyo, Japan) supplemented with 10% fetal bovine serum, 50 units/
ml of penicillin G and 50 Wg/ml of streptomycin at 37‡C in 5% CO2
and 100% relative humidity. For cDNA RDA, the experimental cells
were treated with 10 Wg/ml CHX (Wako, Osaka, Japan) for 30 min
followed by 1 nM TCDD (dissolved in toluene; SUPELCO, Supelco
Park, Bellefonte, PA, USA) for 4 h and the control cells were treated
with CHX and vehicle.
2.2. Extraction of RNA and cDNA synthesis
Total RNA was extracted according to the method of Chomczynski
and Sacchi [14]. Total RNA (600 Wg) was used to purify poly (A)
mRNA by Oligotex mRNA Isolation kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s protocol. Double-stranded
cDNA was synthesized from 2.3 Wg of poly (A) mRNA using a
cDNA synthesis system (Life Technologies, Rockville, MD, USA)
according to the manufacturer’s instructions. cDNA was ¢nally eluted
in 20 Wl of TE (10 mM Tris^HCl, 1 mM EDTA, pH 8.0).
2.3. cDNA representational di¡erence analysis (cDNA RDA)
cDNA RDA was carried out essentially according to the protocol
described by Hubank and Schatz [10]. Control and TCDD-treated
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groups were regarded as Driver and Tester, respectively. The sequen-
ces of the adapter oligonucleotides are shown in Table 1. Brie£y,
cDNAs (1 Wg each) were digested with DpnII. R-24 and R-12-mer
adapters were ligated to the digested cDNAs. Representative ampli-
cons were generated by melting away R-12-mer, ¢lling in the ends and
then amplifying by PCR using the adapter-ligated cDNAs as tem-
plates and R-24-mer as primer. Representative amplicon (100 Wg
each) was digested with DpnII and J-24 and J-12-mers were ligated
only to the Tester. Subtractive hybridization was carried out using
20 Wg of digested Driver amplicon and 0.2 Wg J-ligated Tester ampli-
con at 67‡C for 20 h. J-12-mer was melted away from the hybrid-
ization mix and the hybridized product was ampli¢ed by PCR using
J-24-mer as primer. The PCR product was digested with mung bean
nuclease (MBN; New England Biolabs, Beverly, MA, USA) to re-
move single-stranded DNA and linear ampli¢ed products and the
MBN digested product was ampli¢ed with J-24-mer to generate the
¢rst di¡erence product (DP1). The product of DP1 was digested with
DpnII and N-24 and N-12-mers were ligated to it. Hybridization was
carried out with 20 Wg of digested Driver amplicon and 25 ng of
N-ligated DP1. The second di¡erence product (DP2) was generated
using N-24-mer as primer. The product of DP2 was digested with
DpnII and J-24 and J-12-mers were ligated to it. Hybridization was
carried out with 20 Wg of digested Driver amplicon and 0.5 ng of
J-ligated DP2. The third di¡erence product (DP3) was generated using
J-24-mer as primer and was cloned into pGEM-T vector (Promega,
Madison, WI, USA). The cloned fragments were sequenced by ABI
PRISM dye terminator cycle sequencing ready reaction kit (Perkin
Elmer, Foster City, CA, USA).
2.4. Northern blot analysis
Fifteen micrograms of total RNA from HepG2 cells, cultured in the
presence or absence of TCDD, was subjected to Northern blot anal-
ysis as described previously [15]. The membrane was hybridized with
human E16/CD98LC/hLAT1 cDNA, one of the cDNA fragments
cloned by cDNA RDA, labeled with [K-32P]dCTP (New England Nu-
clear, Boston, MA, USA). The same membrane was rehybridized with
human CYP1A1 and rat glyceryldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA probes. A 288-bp fragment of human CYP1A1
cDNA was cloned by RT-PCR from HepG2 mRNA using primers,
sense: 5P-ACT GCT ATC TCC TGG AGC CTC ATG-3P and anti-
sense: 5P-CTT CTG GTC ATG GTT GAT CTG CCA-3P. The clon-
ing of rat GAPDH was reported previously [15]. Densitometric anal-
ysis was carried out by BAS 2000 bioimage analyzing system (Fuji
¢lm, Tokyo, Japan). E16/CD98LC/hLAT1 mRNA levels were nor-
malized by GAPDH mRNA levels.
2.5. Analysis of amino acid transport
HepG2 cells (1U105) were plated into each well of a 12-well plate
and were cultured for 24 h. The cells were treated with or without
1 nM TCDD for 6 h and then incubated in the transport bu¡er
(1UHanks’ balanced salt solution (Life Technologies) with 10 mM
HEPES-KOH (pH 7.5)) containing 5 WCi (31.45 nmol)/ml 3H-leucine
for 15 or 30 min at 37‡C or on ice (the latter for measuring back-
ground). The cells were washed with ice-cold transport bu¡er twice
and lysed with 400 Wl of 0.5% SDS in 0.2 N NaOH. The lysates were
centrifuged at 12 000 rpm for 10 min to precipitate DNA and aliquots
of 10 Wl of each supernatant were analyzed for radioactivity by a
liquid scintillation counter. Duplicate measurements were performed
and the background was subtracted for each sample. The experiments
were carried out in triplicate for three times.
2.6. Statistical analysis
Statistical analysis was carried out using one-way ANOVA fol-
lowed by Fisher’s protected least signi¢cant di¡erence (PLSD) analy-
sis.
3. Results
HepG2 cells were treated with 10 Wg/ml CHX for 30 min
followed by 1 nM TCDD (Tester) or not (Driver) for 4 h.
After synthesis of cDNAs and DpnII digestion, series of three
subtractions of Driver cDNA population from the Tester
cDNA population and PCR ampli¢cations were carried out.
Fig. 1 shows the pro¢le on the agarose gel electrophoresis of
the ampli¢ed di¡erence products (DP) after each subtraction.
There was a gradual decrease in the number of the products
from DP1 to DP3. Cloning of cDNAs in DP3 and subsequent
sequence analysis showed that most of the clones were inde-
pendent. BLAST search revealed that the nucleotide sequence
of one clone of 178 bp, harboring DpnII sites at both ends,
was completely identical to the region from 853 to 1030 bp of
E16/CD98LC/hLAT1 cDNA (EMBL/DDBJ accession num-
ber AF077866).
To verify the upregulation of E16/CD98LC/hLAT1 mRNA
by TCDD, HepG2 cells were treated with 1 nM TCDD for 0,
1, 3, 6 and 12 h and Northern blot analysis was performed
using the cloned cDNA fragment as a probe. As shown in Fig.
2A, a single band of approximately 3.8 kb was detected in the
absence of TCDD. This size of the band was consistent with
the previous report [16], indicating that E16/CD98LC/hLAT1
mRNA is constitutively expressed in HepG2 cells. TCDD
treatment resulted in signi¢cant increases in the mRNA level,
and the level reached its maximum at 6 h after TCDD treat-
ment and returned to the basal level at 12 h. Similar pattern
of induction was observed in the expression of the CYP1A1
gene, a well characterized TCDD-responsive gene [4].
CYP1A1 mRNA expression increased maximally at 6 h and
returned to the basal level at 12 h. In contrast, GAPDH
mRNA levels were not altered by TCDD treatment. Next
we studied the dose-e¡ect of TCDD on E16/CD98LC/
hLAT1 mRNA level. The cells were exposed to various con-
Fig. 1. Representation of di¡erence products of cDNA RDA. PCR
products at di¡erent steps of cDNA RDA were electrophoresed in a
4% agarose gel. DP1, DP2 and DP3 represent ¢rst, second and
third di¡erence products, respectively. MWM represents molecular
weight marker (PX174/HaeIII digest). The numbers on the right side
indicate the size of the DNA bands in the MWM.
Table 1
Sequences of the oligonucleotides
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centrations of TCDD for 6 h. As shown in Fig. 2B, treatment
with 10315 and 10313 M TCDD did not alter the mRNA level.
Treatment with 10311 M (10 pM) and 1039 M (1 nM) TCDD
induced a signi¢cant increase in the mRNA level. Taken to-
gether, these results demonstrated that the E16/CD98LC/
hLAT1 mRNA level was positively regulated by TCDD.
The next experiment was performed to study the e¡ect of
CHX on TCDD-dependent increase in E16/CD98LC/hLAT1
mRNA. The cells were pretreated with CHX for 30 min and
then treated with TCDD for 0, 1, 3, 6 and 12 h. As shown in
Fig. 3, Northern blot analysis revealed a greater extent of
increase in E16/CD98LC/hLAT1 mRNA levels by TCDD in
the presence of CHX, when compared to its absence (Fig.
2A). It was noted that, in the absence of CHX, the mRNA
level returned to the basal level at 12 h (Fig. 2A), while in its
presence, the mRNA level increased further by six-fold above
the basal level. These observations indicated that the TCDD-
dependent increase in E16/CD98LC/hLAT1 did not require de
novo protein synthesis, and that the presence of protein syn-
thesis inhibitor resulted in superinduction of the mRNA level.
Finally, we examined the functional signi¢cance of the up-
regulation of E16/CD98LC/hLAT1 mRNA by TCDD. One of
the known functions of E16/CD98LC/hLAT1 is transport of
large neutral amino acids into the cells. We, therefore, tested
Fig. 3. Cycloheximide superinduces TCDD-mediated upregulation
of E16/CD98LC/hLAT1 mRNA. HepG2 cells were pretreated with
cycloheximide followed by 1 nM TCDD for 0, 1, 3, 6 and 12 h,
and 15 Wg of total RNA from these cells was subjected to Northern
blot analysis. E16 stands for E16/CD98LC/hLAT1. The experiment
was carried out twice. The data represent mean þ S.D. The asterisks
represent signi¢cant di¡erences from 0 h (*: P6 0.01; **:
P6 0.001).
Fig. 4. TCDD increases transport of 3H-leucine in HepG2 cells.
HepG2 cells were treated with 1 nM TCDD for 6 h followed by in-
cubation in transport bu¡er containing 50 WCi/ml of 3H-leucine for
15 or 30 min. Aliquots of cell lysates were analyzed for radioactivity
using a liquid scintillation counter. Data represent mean þ S.D. The
asterisk represents signi¢cant di¡erence (P6 0.01) between TCDD
(3) and TCDD (+) cells at 30 min.
Fig. 2. TCDD upregulates E16/CD98LC/hLAT1 mRNA expression. A: HepG2 cells were treated with 1 nM TCDD for 0, 1, 3, 6 and 12 h.
Total RNA (15 Wg) from these cells was subjected to Northern blot analysis using E16/CD98LC/hLAT1, CYP1A1 and GAPDH cDNAs as
probes. The asterisks represent signi¢cant di¡erences from 0 h (*: P6 0.01; **: P6 0.001). B: HepG2 cells were treated with indicated concen-
trations of TCDD for 6 h, and 15 Wg of total RNA from these cells was subjected to Northern blot analysis. The asterisk represents signi¢cant
di¡erence from 0 M TCDD (P6 0.01). E16 stands for E16/CD98LC/hLAT1. The experiments were carried out twice. The data represent
mean þ S.D.
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whether TCDD treatment results in increased transport of
3H-leucine into the cells or not. The cells were treated with
1 nM TCDD for 6 h and then incubated for 15 or 30 min in a
transport bu¡er containing 3H-leucine. As shown in Fig. 4, a
signi¢cant increase in the uptake of 3H-leucine was observed
at 30 min.
4. Discussion
In the present study, we succeeded in identifying a novel
TCDD-responsive gene, E16/CD98LC/hLAT1, in human he-
patocytes by utilizing cDNA RDA. E16/CD98LC/hLAT1 was
originally cloned as E16, a transiently expressed protein up-
regulated by the tumor promoter phorbol myristate acetate
(PMA) in Jurkat T-cells, which contained only the 3P-half of
the cDNA [11]. Cloning of the full cDNA revealed that E16 is
identical to the light chain of CD98/4F2 (CD98LC) and L-
type amino acid transporter-1 (hLAT1) [12,13].
Our Northern blot analysis demonstrated that TCDD tran-
siently increased E16/CD98LC/hLAT1 mRNA level without
de novo protein synthesis, suggesting that TCDD may directly
increase the transcription of the gene via activation of AhR/
ARNT. We also observed that the mRNA level can be super-
induced in the presence of protein synthesis inhibitor, CHX.
Two mechanisms may be involved in this phenomenon. In-
hibition of synthesis of new proteins, such as ‘AUUUA’ bind-
ing protein, critical for mRNA degradation might be one of
the mechanisms [17^19]. Indeed, the mRNA contains this
conserved sequence ‘AUUUA’ in the 3P-untranslated region
[11]. Another mechanism might be the inhibition of AhR re-
pressor (AhRR) [20]. AhRR represses the transcriptional ac-
tivity of AhR by competing with AhR in forming a hetero-
dimer with ARNT and by binding with XRE sequence. The
expression of AhRR gene is shown to be induced by AhR/
ARNT which binds to the XRE present in the promoter of
the AhRR gene. These dual e¡ects of CHX on the synthesis of
mRNA binding proteins and AhRR may account for the
superinduction of E16/CD98LC/hLAT1 mRNA.
Human E16/CD98LC/hLAT1 consists of 507 amino acids
with 12 transmembrane domains, indicating that it is an in-
tegral membrane protein [12]. It was demonstrated that E16/
CD98LC/hLAT1 heterodimerizes with the heavy chain of
CD98 (CD98HC) and constitutes the Na-independent amino
acid transport system L which is the major route for the trans-
port of large, neutral amino acids with branched or aromatic
side chains [16,21,22]. CD98HC is constitutively expressed in
almost all tissues and tumor cell lines and functions as a
‘guidance molecule’ for the expression of CD98LC in the
plasma membrane [23]. This might explain the ¢nding that
TCDD-mediated E16/CD98LC/hLAT1 mRNA upregulation
is coupled with increased amino acid transport as demon-
strated by the present study.
It is intriguing to speculate the functional signi¢cance of
TCDD-mediated upregulation of E16/CD98LC/hLAT1
mRNA and increased amino acid transport for the cells.
The mRNA was found to be highly expressed in human colon
cancers, while it was almost undetectable in normal intestine
[24]. It was also reported that E16/CD98LC/hLAT1 was
hardly detectable in adult human tissues such as brain, lung
and liver, but it was detected in various, immortalized cell
lines [11]. In addition, TA1, the rat homologue, was identi¢ed
to be an oncofetal gene which was highly expressed in fetal
liver and in hepatocellular carcinoma [25]. TA1 expression
was shown to be induced by acute and chronic liver injury
mediated by carbon tetrachloride which acts as a tumor pro-
moter in rat models of chronic liver injury [26]. These broad
expression patterns of E16/CD98LC/hLAT1 in rapidly divid-
ing cells and its rapid induction upon treatment with tumor
promoters suggest that it might have a direct functional in-
volvement in the process of cell division or tumor progression.
Recently, it has been documented that overexpression of
CD98 results in malignant transformation of NIH3T3 cells
[27]. TCDD has been shown to act as a potent tumor pro-
moter [28]. These ¢ndings suggest that the TCDD-mediated
increase in E16/CD98LC/hLAT1 expression and the resultant
increase in uptake of amino acid may be coupled with cell
proliferation and tumor progression.
CD98 is involved not only in the cellular uptake of amino
acids, but also in the activation of integrin signaling pathway,
calcium homeostasis, cellular activation of lymphocytes and
cell fusion [29]. It remains to be studied whether these pleio-
tropic functions of CD98 are related to the biological e¡ects
of TCDD or not.
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